EP4289446A2 — Method and composition for treating ocular hypertension and glaucoma
Assigned to Santen Pharmaceutical Co Ltd · Expires 2023-12-13 · 2y expired
What this patent protects
The present invention relates to a method for increasing aqueous solubility and improving stability of tafluprost in an aqueous ophthalmic solution, comprising the steps of preparing an aqueous ophthalmic solution containing 0.0010-0.0025% tafluprost, 0.075% polysorbate 80, 0.005…
USPTO Abstract
The present invention relates to a method for increasing aqueous solubility and improving stability of tafluprost in an aqueous ophthalmic solution, comprising the steps of preparing an aqueous ophthalmic solution containing 0.0010-0.0025% tafluprost, 0.075% polysorbate 80, 0.005-0.2% stabilizing agent and substantially no preservatives, and packaging the preservative-free ophthalmic solution in a container consisting essentially of polyethylene.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.